The increased metastatic spread of a preexisting tumor, as observed in preclinical models, has so far not been reported in clinical studies analyzing the development of metastatic disease in type 2 diabetes patients treated with DPP-IV inhibitors. This evidence concerns the gene DPP4 and metastatic neoplasm.